Plasma superwarfarin levels and vitamin K1 treatment in dogs with anticoagulant rodenticide poisoning

被引:21
|
作者
Robben, JH
Kuijpers, EAP
Mout, HCA
机构
[1] Univ Utrecht, Fac Vet Med, Dept Clin Sci Compan Anim, Intens Care Unit, NL-3508 TD Utrecht, Netherlands
[2] Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands
[3] Natl Inst Publ Hlth & Environm, Natl Poisons Control Ctr, NL-3720 BA Bilthoven, Netherlands
关键词
D O I
10.1080/01652176.1998.9694831
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
The plasma concentration, plasma half-life (t(1/2)), and mean residence time (MRT) of rodenticide anticoagulants were determined in 21 dogs in which a preliminary diagnosis of anticoagulant rodenticide poisoning had been made. Brodifacoum, difethialone, and difenacoum were detected by high-performance liquid chromatography (HPLC) in the plasma of 13, 3, and 2 dogs, respectivery. At presentation the plasma concentration ranged from below the detection limit (10 ng/L) to 851 ng/L. Toxin could not be detected in 3 dogs, despite these animals showing characteristic coagulation disturbances and a positive response to therapy with vitamin K-1. In 7 dogs the estimated t(1/2) of brodifacoum ranged from 0.9 to 4.7 (median 2.4) days with a MRT of 1.9 to 3.7 (median 2.8) days. In 2 dogs the individual t(1/2) Of difethialone was 2.2 and 3.2 days and the MRT was 2.3 and 2.8 days, respectively. Two dogs died during emergency treatment. Treatment in the remaining 19 dogs consisted of the administration of vitamin K-1 and supportive therapy. The dose of vitamin K-1 was reduced in a stepwise manner as long as the prothrombin time remained within physiological limits. The variation in initial plasma concentrations of the anticoagulants combined with the results of treatment support the idea that an individual therapeutic approach is warranted.
引用
收藏
页码:24 / 27
页数:4
相关论文
共 50 条
  • [31] Retrospective evaluation of vitamin K1 usage to reverse the anticoagulant effect of warfarin.
    Fan, JY
    Armitstead, JA
    Adams, AG
    Davis, GA
    PHARMACOTHERAPY, 2002, 22 (10): : 1343 - 1344
  • [32] THE EFFECT OF HIGH-DOSE VITAMIN-K1 (K1) PROPHYLAXIS ON PLASMA-LEVELS OF K1 IN INFANTS OF VERY-LOW-BIRTH-WEIGHT (IVLBW)
    KHALIFEH, MT
    DWECK, HS
    SIMON, P
    REALE, MR
    ROSENFELD, L
    PEDIATRIC RESEARCH, 1991, 29 (04) : A220 - A220
  • [33] Cholestyramine: an inexpensive but overlooked treatment for long-acting anticoagulant rodenticide (LAAR) poisoning
    Rubinstein, Israel
    Kaul, Malvika
    Feinstein, Douglas L.
    TOXICOLOGY COMMUNICATIONS, 2024, 8 (01)
  • [34] IDENTIFICATION OF ABNORMAL PROTHROMBIN AND VITAMIN-K1, K1 EPOXIDE LEVELS IN NEONATES
    SOLL, RF
    LYNCH, MB
    BOVILL, EG
    CHURCH, WR
    SADOWSKI, J
    PEDIATRIC RESEARCH, 1990, 27 (04) : A269 - A269
  • [35] Vitamin K3 is not an alternative to Vitamin K1
    von Lüttwitz, M
    Schulz, H
    TIERARZTLICHE UMSCHAU, 2000, 55 (03): : 155 - +
  • [36] The levels of vitamin K1 and K2 analogues in femur of diabetic rat
    Wakabayashi, H
    Imai, S
    Yamazaki, K
    Kamei, J
    Onodera, K
    JOURNAL OF PHARMACOLOGICAL SCIENCES, 2004, 94 : 184P - 184P
  • [37] The levels of vitamin K1 and K2 analogues in human and rat bone
    Wakabayashi, H
    Takahashi, A
    Kamei, J
    Onodera, K
    BONE, 2003, 32 (05) : S106 - S106
  • [38] Influence of anticoagulant therapy with vitamin K antagonists on plasma levels of coagulation factor VIII
    Passamonti, Serena Maria
    Bucciarelli, Paolo
    Bader, Rossella
    Martinelli, Ida
    THROMBOSIS RESEARCH, 2010, 126 (03) : 243 - 245
  • [39] Microalgae as a source of vitamin K1
    Tarento, Thomas D. C.
    McClure, Dale D.
    Vasiljevski, Emily
    Schindeler, Aaron
    Dehghani, Fariba
    Kavanagh, John M.
    ALGAL RESEARCH-BIOMASS BIOFUELS AND BIOPRODUCTS, 2018, 36 : 77 - 87
  • [40] Supply of vitamin K1 tablets
    不详
    VETERINARY RECORD, 2010, 166 (04) : 93 - 93